Literature DB >> 26576793

Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor.

Toshimitsu Tsugu1,2, Shiro Iwanaga3, Mitsushige Murata4, Keiichi Fukuda5.   

Abstract

Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.

Entities:  

Keywords:  Bioprosthetic valve replacement; Carcinoid heart disease; Cartinoid tumor; Echocardiography

Mesh:

Year:  2015        PMID: 26576793     DOI: 10.1007/s10396-015-0621-9

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  9 in total

1.  Early bioprosthetic valve deterioration after carcinoid plaque deposition.

Authors:  Javier G Castillo; Farzan Filsoufi; Parwis B Rahmanian; Jerome S Zacks; Richard R P Warner; David H Adams
Journal:  Ann Thorac Surg       Date:  2009-01       Impact factor: 4.330

2.  Ovarian strumal carcinoid tumor responsible for carcinoid heart disease.

Authors:  L Brunaud; L Antunes; H Sebbag; L Bresler; J P Villemot; P Boissel
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-09       Impact factor: 2.435

3.  Carcinoid heart disease in association with a primary ovarian carcinoid tumor: diagnostic role of echocardiography.

Authors:  D M Franko; M Berger
Journal:  Echocardiography       Date:  2000-08       Impact factor: 1.724

Review 4.  Carcinoid heart disease.

Authors:  Alain M Bernheim; Heidi M Connolly; Timothy J Hobday; Martin D Abel; Patricia A Pellikka
Journal:  Prog Cardiovasc Dis       Date:  2007 May-Jun       Impact factor: 8.194

5.  Carcinoid heart disease associated with primary ovarian carcinoid tumor.

Authors:  Nithima Chaowalit; Heidi M Connolly; Hartzell V Schaff; Maurice J Webb; Patricia A Pellikka
Journal:  Am J Cardiol       Date:  2004-05-15       Impact factor: 2.778

6.  Primary ovarian carcinoid tumor in combination with carcinoid heart disease; a case report.

Authors:  S G Oei; M D Kloosterman; A T Verhoeven
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1989-05       Impact factor: 2.435

7.  Progressive carcinoid heart disease after resection of primary ovarian carcinoid.

Authors:  M A Wilkowske; L C Hartmann; C J Mullany; T Behrenbeck; L K Kvols
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

8.  Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor.

Authors:  Johanna M Zuetenhorst; Johannes M G M Bonfrer; Catharina M Korse; Rob Bakker; Harm van Tinteren; Babs G Taal
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  [Isolated carcinoid tumor of the ovary disclosed by tricuspid insufficiency].

Authors:  O Nallet; S Nahon; B Cormier; L Cadoux; B Iung; S Mazouz; F Vitaux; J Richemond; J P Couetil; J Sergent
Journal:  Arch Mal Coeur Vaiss       Date:  2003-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.